Cell Therapeutics vor Tounaround?
Jetzt liegen wir umgerechnet schon bei 1,265 €
Heute schaffen wir noch die 1,80 US$
Friday, 26 June 2009 13:23
http://biomedreports.com/articles/most-popular/...c-heb-and-cpd-.html
Will getting FDA approval for pixantrone be of much help to Cell Therapeutics if there is still such a highly adverse reaction to the therapy? Sure, there will be a market for the drug, which will be used to treat lymphoma, leukemia, and breast cancer, but it might not be the billion-dollar blockbuster that some investors were hoping for.
Cell Therapeutics continues to dilute share holder value while hoping the FDA grants it mercy. That could still happen, or a buyout could occur, but either would not net a reasonable change to valuation. Pixantrone, if approved, has a very limited market base, far below the $600M - $1 billion that management predicts. Hope, while waiting on the FDA hinges on refinancing debt at $0.20-$0.30 on the dollar. Possible, but not likely. In the meantime the share count is sky high and growing, which would disperse most of any EPS or buyout that developed.
Sure, it's a bit speculative...there's a chance the two drugs that are pending approval don't get through. And there's also some question about whether these drugs will be million-dollar drugs or billion dollar drugs. But the drug no one is even looking at is their novel minor-groove binding cancer killer (brostacillin, sp?) further down the pipeline. Nova RX is the only drug developer out there with a candidate that has as much potential. Their balance sheet is getting clean, and once they have some solid income, life will be good.
www.fool.com/investing/high-growth/2009/06/02/...hake-the-market.aspx
Heute kommen doch NEWS ob CTIC eventuell im Russel aufgenommen wird.
Also ganz entspannt zuschauen und geniesen.
Könnte richtig spaßig werden als Aktienbesitzer die nächsten Stunden und Tage.
Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
Press Release
SEATTLE, June 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has been added to the Russell 3000®, Russell 2000® and Russell Global® Indexes posted by Russell Investments on June 29, 2009 on www.russell.com. Russell Investments reconstitutes its family of U.S. and global equity indexes on an annual basis.
Related Quotes
Symbol Price Change
CTIC 1.78 -0.07
{"s" : "ctic","k" : "c10,l10,p20,t10","o" : "","j" : ""} Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the last trading day of May, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. Membership in the Russell Global® Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $4 trillion in assets currently are benchmarked to them. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell Indexes is available at http://www.russell.com/Indexes/performance/default.asp.
Heute locker über 2 Dollar.Wartet ab bis die Amis aufstehen und lesen.Die zittrigen die gestern kurz vor US Börsenscchluß raus sind da Sie dachten die NEWS würde negativ ausfallen dürften die esten sein die sich wieder eindecken wollen.